Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13507-13512. doi: 10.1073/pnas.1714386114. Epub 2017 Dec 5.
Interleukin 1 (IL-1) receptor-associated kinases (IRAKs) are serine/threonine kinases that play critical roles in initiating innate immune responses against foreign pathogens and other types of dangers through their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathways. Upon ligand binding, TLRs and IL-1Rs recruit adaptor proteins, such as myeloid differentiation primary response gene 88 (MyD88), to the membrane, which in turn recruit IRAKs via the death domains in these proteins to form the Myddosome complex, leading to IRAK kinase activation. Despite their biological and clinical significance, only the IRAK4 kinase domain structure has been determined among the four IRAK family members. Here, we report the crystal structure of the human IRAK1 kinase domain in complex with a small molecule inhibitor. The structure reveals both similarities and differences between IRAK1 and IRAK4 and is suggestive of approaches to develop IRAK1- or IRAK4-specific inhibitors for potential therapeutic applications. While the IRAK4 kinase domain is capable of homodimerization in the unphosphorylated state, we found that the IRAK1 kinase domain is constitutively monomeric regardless of its phosphorylation state. Additionally, the IRAK1 kinase domain forms heterodimers with the phosphorylated, but not unphosphorylated, IRAK4 kinase domain. Collectively, these data indicate a two-step kinase activation process in which the IRAK4 kinase domain first homodimerizes in the Myddosome, leading to its -autophosphorylation and activation. The phosphorylated IRAK4 kinase domain then forms heterodimers with the IRAK1 kinase domain within the Myddosome, leading to its subsequent phosphorylation and activation.
白细胞介素 1(IL-1)受体相关激酶(IRAKs)是丝氨酸/苏氨酸激酶,在通过 Toll 样受体(TLR)和白细胞介素 1 受体(IL-1R)介导的信号通路中,它们在启动针对外来病原体和其他类型危险的固有免疫反应中发挥关键作用。配体结合后,TLRs 和 IL-1Rs 将衔接蛋白(如髓样分化初级反应基因 88(MyD88))募集到膜上,MyD88 蛋白上的死亡结构域又将 IRAKs 募集到复合物中,从而导致 IRAK 激酶的激活。尽管 IRAK 具有生物学和临床意义,但在 IRAK 家族的四个成员中,只有 IRAK4 的激酶结构域结构已被确定。在这里,我们报告了人 IRAK1 激酶结构域与小分子抑制剂复合物的晶体结构。该结构揭示了 IRAK1 和 IRAK4 之间的相似性和差异性,并提示了开发 IRAK1 或 IRAK4 特异性抑制剂用于潜在治疗应用的方法。虽然 IRAK4 激酶结构域在未磷酸化状态下能够发生同源二聚化,但我们发现 IRAK1 激酶结构域无论其磷酸化状态如何,均为组成型单体。此外,IRAK1 激酶结构域与磷酸化但非未磷酸化的 IRAK4 激酶结构域形成异源二聚体。总之,这些数据表明 IRAK4 激酶结构域在 Myddosome 中首先发生同源二聚化,导致其自身磷酸化和激活的两步激酶激活过程。然后,磷酸化的 IRAK4 激酶结构域与 Myddosome 内的 IRAK1 激酶结构域形成异源二聚体,导致其随后的磷酸化和激活。